Achieve Life Sciences enters $50M ATM equity offering with Jefferies for cytisinicline

ACHIEVE LIFE SCIENCES, INC.

Entered Open Market Sale Agreement with Jefferies for at-the-market offering of up to $50M of common stock.
Jefferies receives up to 3% commission; company has no obligation to sell and may suspend at any time.
Proceeds to fund clinical development of cytisinicline for smoking cessation and general corporate purposes.
Offering made under existing S-3 registration statement filed June 28, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.